Lipoprotein(a) presents the proceedings of the International Symposium, held in Chicago, Illinois, on December 2–3, 1988. It discusses the different aspects of the research on lipoprotein(a), commonly referred to as Lp(a). It covers a wide range of topics, including comparative biology, metabolism, structure, epidemiology, and treatment. Comprised of 15 chapters, the book starts with an overview of the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD), followed by a discussion on recent findings and developments. It then considers the relationship between elevated plasma Lp(a) and the inherited risk factor for the development of coronary heart disease. The reader is also introduced to the various components of Lp(a), which include neutral lipids, polar lipids, apoprotein(a), and apoprotein B. Other chapters discuss the specific functions of apolipoproteins in plasma lipid metabolism, which determine the fate of the various lipoprotein particles in plasma. This book will be of benefit to cardiologists and medical practitioners.

Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for cardiovascular vascular disease. Data from case control, epigenetic and mendelian randomization studies indicate that people with elevated Lp(a) have a two-fold to four-fold increased risk of cardiovascular events compared to people with low Lp(a) levels. Despite this risk, awareness of Lp(a) is still very low among health care providers. Even cardiologists often overlook Lp(a), in part because Lp(a) is not as well-understood as other risk factors and treatment options are still very limited. This book offers an authoritative and comprehensive overview of Lipoprotein(a). It provides an in-depth review of all aspects of Lp(a), from pathophysiology to metabolism. Chapters offer the reader a contemporary view of the important roles of Lp(a) as a risk factor for cardiovascular disease. In addition, this volume discusses the clinical implications of elevated Lp(a) and current and future therapies. Lipoprotein(a) is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.

Diabetes mellitus has become epidemic on a global scale, and millions of new cases are diagnosed every year. The epidemic of diabetes mellitus is expected to result in one of the steepest rises in human morbidity and mortality ever observed outside of wartime. Insulin resistance is a hallmark of pre-diabetes and type 2 diabetes mellitus, and is characterized by impaired insulin-signaling transduction. Authoritative and comprehensive, Lipoproteins in Diabetes Mellitus details the many changes wrought by insulin resistance and diabetes mellitus on lipid and lipoprotein metabolism. The book begins by summarizing the various techniques to measure lipoproteins and their subclasses. The mechanisms by which insulin resistance and diabetes mellitus increase risk for atherosclerosis, diabetic retinopathy, and diabetic nephropathy are then explored in detail. Finally, the effects of lifestyle modification and the results of clinical trials using established and investigational drugs are discussed. An invaluable contribution to the literature, Lipoproteins in Diabetes Mellitus is a comprehensive reference on the clinical and scientific aspects of lipoproteins in diabetes. It will have a long-lasting and significant effect on the medical management of people with diabetes.

Clinical Lipidology, a companion to Braunwald's Heart Disease, is designed to guide you through the ever-changing therapeutic management of patients with high cholesterol levels. From basic science to pathogenesis of atherothrombotic disease, to risk assessment and the latest therapy options, this medical reference book offers unparalleled coverage and expert guidance on lipidology in a straightforward, accessible, and user-friendly style. Get authoritative guidance from some of the foremost experts in the field. Easily access key content with help from treatment algorithms. Access options and evidence-based solutions for every type of patient scenario, as well as the latest clinical guidelines and clinically relevant evidence on risk assessment, special patient populations, and therapy, including recently approved and experimental therapies. Remain at the forefront of the cardiology field with up-to-date chapters on treatment guidelines; diet, exercise, and weight loss; pharmacologic therapies such as statins, omega-3 fatty acids, and combination therapy; evolving targets of therapy such as PCSK9 inhibition, CETP inhibition, and inflammation Prepare for special patient populations such as children and adolescents; women and the elderly; transplant recipients; HIV patients; and those with chronic renal disease, familial hypercholesterolemia, other severe hypercholesterolemias, diabetes, or other metabolic syndromes. Take advantage of a format that follows that of the well-known and internationally recognized Braunwald's Heart Disease. Expert Consult eBook version included with purchase.

In this Handbook of Experimental Pharmacology on “High Density Lipoproteins – from biological understanding to clinical exploitation” contributing authors (members of COST Action BM0904/HDLnet) summarize in more than 20 chapters our current knowledge on the structure, function, metabolism and regulation of HDL in health and several diseases as well as the status of past and ongoing attempts of therapeutic exploitation. The book is of interest to researchers in academia and industry focusing on lipoprotein metabolism, cardiovascular diseases and immunology as well as clinical pharmacologists, cardiologists, diabetologists, nephrologists and other clinicians interested in metabolic or inflammatory diseases.